Andrea Terron

Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009

Niklas Andersson, Maria Arena, Domenica Auteri et al. · EFSA Journal · 2018 · 535 citations · Full text

Pharmacy, Toxicology, Environmental Toxicology +16

Guidance on the use of the weight of evidence approach in scientific assessments

Diane Benford, Michael Jeger, Helle Katrine Knutsen et al. · EFSA Journal · 2017 · 408 citations · Full text

Education, Science Education, Evidence-based Practice +16

Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes

Ellen Fritsche, Philippe Grandjean, Kevin M. Crofton et al. · Toxicology and Applied Pharmacology · 2018 · 122 citations · Full text

Pharmacy, Neuroscience, Toxicology +17

Early Antiangiogenic Activity of SU11248 Evaluated <i>In vivo</i> by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma

Pasquina Marzola, Anna Degrassi, Laura Calderan et al. · Clinical Cancer Research · 2005 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

Shem Patyna, Claudio Arrigoni, Andrea Terron et al. · Toxicologic Pathology · 2008 · 89 citations

Medicine, Oncology, Pharmacology +13